Global Immunomodulator Market Overview 2024: Size, Drivers, And Trends

Written by

The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Strong Market Expansion from 2023 to 2024

The immunomodulator market has witnessed significant growth, expanding from $204.37 billion in 2023 to $219.94 billion in 2024.
The market is growing at a compound annual growth rate (CAGR) of 7.6%.
Key drivers of growth include the development of healthcare infrastructure, increased patient awareness, and a growing aging population.
The rising incidence of autoimmune diseases and the introduction of biologic drugs have also played a pivotal role.

Future Growth Projections: 2024 to 2028

The market size is expected to grow further, reaching $297.15 billion by 2028 at a CAGR of 7.8%.
Growth factors include an increasing patient preference for non-invasive treatments, regulatory approvals, and comprehensive health insurance coverage.
The expansion of immunomodulatory drugs and rising government healthcare expenditures will also contribute to market growth.
Emerging trends such as advancements in biotechnology, personalized medicine, and immuno-oncology are set to shape the future of the market.

Chronic Diseases Driving Market Expansion

The rise in chronic diseases, which are long-lasting and persist for extended periods, is a significant growth driver for the immunomodulator market.
Factors contributing to the prevalence of chronic diseases include aging populations, lifestyle choices, and genetic predispositions.
Immunomodulators offer valuable therapeutic options, including immune response modulation, inflammation reduction, and symptom control.
According to the World Health Organization, 74% of global deaths are due to non-communicable diseases (NCDs) or chronic diseases.
Specific causes of death include cardiovascular diseases (17.9 million), cancer (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million).

Key Players in the Immunomodulator Market

Major companies in the market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, and Novartis AG.
Other significant players are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, and Gilead Sciences Inc.

Innovation in Non-Immunosuppressive Immunomodulators

Companies are increasingly focused on developing non-immunosuppressive products that provide targeted immune modulation without compromising overall immune function.
In February 2024, Nuvig Therapeutics, Inc. began early-stage clinical trials for NVG-2089, a next-generation immune modulator.
NVG-2089 targets type II Fc receptors, reducing autoimmune dysregulation and showing promise in treating inflammatory myopathies and severe dermatologic autoimmune diseases.
The FDA has granted fast-track designation for NVG-2089’s development in bullous pemphigoid.

Strategic Acquisitions Driving Market Growth

In February 2022, Equillium, Inc. acquired Bioniz Therapeutics Inc., significantly expanding its immunology pipeline.
The acquisition brought two first-in-class clinical-stage assets and a proprietary product discovery platform to Equillium’s portfolio.
Bioniz Therapeutics focuses on cytokine-targeted medicines for immuno-inflammatory disorders and cancer, contributing to the broader immunomodulator market.

Market Segmentation and Regional Insights

The immunomodulator market is segmented by product type into immunosuppressants, immunostimulants, and other product types.
Distribution channels include hospital pharmacy, online pharmacy, retail pharmacy, and other channels.
The market applications range across oncology, respiratory conditions, human immunodeficiency virus (HIV), and other areas.
North America led the market in 2023, while Asia-Pacific is expected to be the fastest-growing region during the forecast period.

More posts